We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| IntelliAM AI plc | INT | Aquis Stock Exchange | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade | |
|---|---|---|---|---|
| 0.00 | 0.00% | 110.00 | 06:58:37 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 110.00 | 110.00 | 110.00 | 110.00 |
| Top Posts |
|---|
Posted at 03/7/2024 14:45 by hedgehog 100 Current share price 3rd. July 2024: 105p16,382,534 shares in issue Market capitalisation: £17.2016M. "Transforming business with AI-powered Asset Management Unlock a new dimension of efficiency, innovation and success." "About IntelliAM AI Plc IntelliAM AI Plc is a software company leveraging the power of AI and machine learning in the manufacturing industry. IntelliAM uses AI models to proactively increase operating efficiency of the existing assets of the Company’s manufacturing clients. The Company achieves this by harnessing vast amounts of data from the client’s machines and operational systems processed through the IntelliAM platform to provide actionable insights for clients that encompass a broad range of areas, such as productivity, reliability and supply-chain optimisation, as well as energy efficiency and sustainability." 03 Jul 24 07:00 IntelliAM AI PLC - AQSE Only - Admission to Trading & First Dealings "Admission to Trading on AQSE and First Day of Dealings IntelliAM AI plc (AQSE: INT), the software company leveraging the power of AI and machine learning in the manufacturing industry, is pleased to announce that dealings in its Ordinary Shares of £0.005 each (Ordinary Shares) will commence from 8:00 am today, 3 July 2024, on the Aquis Stock Exchange Growth Market under the ticker symbol INT and ISIN number --GB00BR56LJ77. On Admission, and following a Placing that raised gross proceeds of £5,079,989, the Company will have 16,382,534 Ordinary Shares in issue and the market capitalisation of the Company will be approximately £15,399,582. Tomorrow, Thursday 4 July, the Company will complete the acquisition of 53 North and issue 2,759,042 Consideration Shares. Therefore, on 4 July the Company will have 19,141,576 shares in issue and, at the Placing Price of 94p, this would represent a market capitalisation of £17,993,081. A further announcement will be made tomorrow and details of the acquisition, and any terms not defined in this announcement, can be found in the Company's Admission Document at: About IntelliAM IntelliAM uses AI models to proactively increase operating efficiency of the existing assets of the Company's manufacturing clients. The Group achieves this by harnessing vast amounts of data from the client's machines and operational systems processed through the IntelliAM platform to provide actionable insights for clients that encompass a broad range of areas, such as productivity, reliability and supply-chain optimisation, as well as energy efficiency and sustainability. Tom Clayton, Chief Executive Officer of IntelliAM, said: "We are delighted to be joining the AQSE Growth Market at a time when we have combined our established manufacturing asset management consultancy with our more recently developed and launched IntelliAM AI platform. We believe that this platform has immense and proven potential to reduce unscheduled manufacturing downtime, improve producer operating efficiencies and thereby increase our clients' profitability." Enquiries: IntelliAM AI plc +44 114 299 5007 Tom Clayton, Chief Executive Officer Daud Khan, Chief Financial Officer Oberon Capital - AQSE Corporate Adviser and Broker +44 203 179 5300 Adam Pollock Mike Seabrook Jessica Cave Square1 Consulting - Financial PR +44 207 929 5599 David Bick +44 7831 381201" "IntelliAM AI starts trading on AQSE with £15 million market cap 03 July 2024, 12:03 Source - Alliance News The software company, leveraging the power of AI and machine learning in the manufacturing industry, said following a placing that raised £5.1 million gross, it will have 16.4 million shares in issue with a market capitalisation of around £15.4 million. The placing price was 94 pence per share. Shares in IntelliAM rose 11% to 104.0p each on Wednesday in London, implying a market value of around £17.1 million. It added that on Thursday, it will complete the acquisition of 53 North and issue 2.8 million consideration shares, meaning there will be 19.1 million shares in issue. Including the shares to be issued as part of the 53 North deal, the current 104p share price suggests a market value of around £19.9 million. Copyright 2024 Alliance News Ltd. All Rights Reserved." |
Posted at 14/7/2008 19:24 by jotoha1 I have instructed top litigation lawyers with the help of 12 other investors to go after Thomas for misleading shareholders of a listed company, we expect to have our first hearing in the high court within 6 months, we are intending to go after all personal assets including all hidden assets ! |
Posted at 09/7/2008 10:06 by nils214 TF I didn't go with this one...was always very weary about it, it seemed to be too good to be true that the future earnings growth etc was going to result in the share price going up 4 or 500% and so it has been proven. Feel sorry for investors who have once again been misled not only by the company but also by the independent research notes...none of them ever mentioned a caveat about cashflow and refinancing.Good luck with the next rns |
Posted at 20/6/2008 11:32 by ged5 Buys are outnumbering the sells in the past week but still have some catching up to do. Since the results there has been a sell off. Hopefully we're nearing the bottom.I think we need to remind ourselves of the very positive broker report produced by Robin Speakman:- "IMD has reported a solid set of interim results, above our expectations at the revenue, operating profit, adjusted PBT and EPS levels. The period saw further restructuring costs and an aborted acquisition which revealed an exceptional cost of c£1.3m the outlook remains robust in the defensive healthcare sector (we expect growth of between 7% and 11% in the medical equipment and consumables markets). We expect the current half through to August 2008 to show a clean period of profitable trading and this pulls through an upgrade to our expectations (for the current year and thereafter). The long-term outlook remains positive for organic growth, building upon the acquisitions made to date. IMD's strategy remains to build operations by buying businesses and to grow these by consolidation of these into the group sales and distribution infrastructure.... ...IMD has seen considerable management change in the period with a new executive team taking over group operations under the experienced Bill McGrath. We believe that this change heralds the emergence of revenue and profit momentum for the company. IMD's operations are growing and profitable and we now expect the company to begin to generate free cash flows. The valuation is inexpensive on a FY2009F PER of c3.6x (EV/EBITDA 3.0x) and a free cash flow yield of over 27%. We also note that the company trades well below its prospective NAV per share of c6.1p." It's also worth noting that the share price was originally marked up on the day of results before the cash position freaked investors out and caused them to sell. Maybe they've all gone now and slowly buyers will return. I feel happier with the company at the moment. I was fearful of the company going bust and it may still do so. However if it survives and I believe there is every indication that it will do so(and expand when the opportunity arises) then we have a company that should give very handsome returns. All imo |
Posted at 28/5/2008 14:40 by tornadodown Cyber that strategy is one which I have also used to great success. It is not often that one can find an undervalued company where the price has been slashed due to a distressed seller.The results today show that the company is making progress and the Broker Note backs this up giving fair value today at over 6p. Many investors will look for undervalued companies which could produce a multiple of their investment going forward. The potential that could open up if FDA approval is received is also tremendous and the market will need to wake up to this companies potential shortly. |
Posted at 30/4/2008 16:51 by tornadodown This is the type of opportunity where the normal private investor can make serious returns on their investment. |
Posted at 29/4/2008 16:11 by cyberpost Gedif there was a change in trading which was materially different from forecasts then they would have been obliged to issue an RNS. The fact that no trading statement was made either way (before close period), implies trading is inline with expectation which means its profitable. Its the lack of substantive news for such a long period that is hitting the share price. Bored investors selling, and with no buyers the market makers drop down the price. I am sure once the results are announced the price will bounce back very strongly. |
Posted at 20/3/2008 08:36 by ged5 I also agree with the comments here about shorting. Although we can spreadbet (although I've never done so) we can't compete on a level playing field. Why one set of investors is allowed to borrow shares to sell and not the private investors is beyond belief. I can't see that it helps companies either. Haven't some companies folded because of persistent shorting?That said this company doesn't help itself. The management make it difficult to speak to them, they don't answer e-mails and they don't see a reason for updating the very people who are providing them with money. I just hope they treat their customers a lot better than they do us. |
Posted at 29/8/2007 12:52 by soldi JTK - in a nutshell (for myself as a newbie investor), why is the inference not valid? |
Posted at 29/8/2007 10:42 by jotoha1 Hope you guys realise but some very hurt investors are looking to instruct a class action against Thomas and co, for his actions with FAR...INTERESTING DEVELOPMENT TO SAY THE LEAST! |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
